Hepatitis c Trials in Frankfurt, Germany
Conditions / Hepatitis c / Frankfurt, Germany
Hepatitis c is a medical condition with active clinical research programs worldwide.
24 total trials for this combination
Showing top 10 of 24 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01485991 | TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy | COMPLETED | PHASE3 |
| NCT01474811 | HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network | COMPLETED | — |
| NCT01318694 | Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants | COMPLETED | PHASE3 |
| NCT01492426 | Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection | COMPLETED | PHASE3 |
| NCT03707080 | Direct Acting Antiviral-Post Authorization Safety Study | COMPLETED | — |
| NCT01492504 | Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial | COMPLETED | — |
| NCT00627926 | A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV) | COMPLETED | PHASE3 |
| NCT01215643 | Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants | COMPLETED | PHASE2 |
| NCT00535847 | A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy | COMPLETED | PHASE2 |
| NCT00420784 | A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3) | COMPLETED | PHASE2 |